A review of the side effects of CAR T-cell therapy, including CRS, ICANS, tumor lysis syndrome, and late-onset toxicities, and management strategies.

During a live event, Catherine J. Lee, MD, MS, discussed the mechanism of action of approved therapies for chronic ...

In myeloma treatment, acute CRS is a common but treatable AE associated with CAR T-cell therapy and bispecific antibodies, ...

Bispecific antibodies have become component in the arsenal of treatments for hematologic malignancies; management of their side effects is crucial to their success.

Aptevo Therapeutics reports strong remission rates in AML patients using mipletamig plus ven/aza, with Cohort 2 enrollment ...

Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor ...

Results showed the agent lessened severity of cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome (ICANS) for a majority of treated patients. “We expected to see ...